RxDoctor Payments DataLook up a doctor →

Donald Wilfong, MD

Internal Medicine · Cheswick, PANPI 1346230844

Payments from drug & device makers

$195,215in general payments, 2019–2025

Across 1,854 payments — averaging $105.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$63K
  • Johnson & Johnson$53K
  • Boehringer Ingelheim$19K
  • AstraZeneca$16K
  • Lilly USA, LLC$13K
  • Amgen$11K
  • plus $21K from 36 others

What the payments were for

  • Consulting fees$15,2038%
  • Speaking & faculty fees$136,24170%
  • Travel & lodging$8,3634%
  • Food & beverage$35,35618%
  • Education$530%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$195,215 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$123,495
Medicare patients
173
Services billed
1,084

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide165$189,129
EliquisApixaban178$151,002
Trelegy ElliptaFluticasone/Umeclidin/Vilanter202$149,540
XareltoRivaroxaban153$114,620
JardianceEmpagliflozin110$112,995
EntrestoSacubitril/Valsartan79$64,558
FarxigaDapagliflozin Propanediol74$63,500
Tresiba Flextouch U-200Insulin Degludec45$51,555
TrulicityDulaglutide31$33,871
MounjaroTirzepatide23$28,479
TradjentaLinagliptin23$24,326
JanuviaSitagliptin Phosphate26$21,413
RybelsusSemaglutide11$17,614
TrintellixVortioxetine Hydrobromide16$15,900
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr29$15,823

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$63,072$206,743176 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$3,079$175,044251 claims
PfizerEliquis$641$151,002178 claims
Boehringer IngelheimJardiance, Tradjenta$18,892$137,321133 claims
Johnson & JohnsonXarelto$52,508$114,620153 claims
AstraZenecaFarxiga, Breztri Aerosphere$16,231$72,59089 claims
NovartisEntresto$1,399$64,55879 claims
Lilly USA, LLCTrulicity, Mounjaro$12,690$62,35054 claims
MerckJanuvia$249$21,41326 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$758$15,90016 claims
AbbVieLinzess, Synthroid$1,232$13,26180 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Cheswick

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →